Adaptive single-KIR<sup>+</sup>NKG2C<sup>+</sup> NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia

Alvaro Haroun-Izquierdo(Karolinska Institutet), Marianna Vincenti(Oslo University Hospital), Herman Netskar(Oslo University Hospital), Hanna van Ooijen(Science for Life Laboratory), Bin Zhang(University of Minnesota), Laura E. Bendzick(University of Minnesota), Minoru Kanaya(Oslo University Hospital), Pouria Momayyezi(Karolinska Institutet), Shuo Li(Oslo University Hospital), Merete Thune Wiiger(Oslo University Hospital), Hanna Julie Hoel(Oslo University Hospital), Silje Zandstra Krokeide(Oslo University Hospital), Veronika Kremer(Karolinska Institutet), Geir E. Tjønnfjord(Oslo University Hospital), Stéphanie Berggren(Karolinska University Hospital), Kristina Wikström(Karolinska University Hospital), Pontus Blomberg(Karolinska University Hospital), Evren Alici(Karolinska Institutet), Martin Felices(University of Minnesota), Björn Önfelt(Science for Life Laboratory), Petter Höglund(Karolinska University Hospital), Bahram Valamehr(Fate Therapeutics (United States)), Hans‐Gustaf Ljunggren(Karolinska Institutet), Andreas T. Björklund(Karolinska University Hospital), Quirin Hammer(Karolinska Institutet), Lise Kveberg(Oslo University Hospital), Frank Cichocki(University of Minnesota), Jeffrey S. Miller(University of Minnesota), Karl‐Johan Malmberg(Oslo University Hospital), Ebba Sohlberg(Karolinska Institutet)
Journal for ImmunoTherapy of Cancer
November 1, 2022
Cited by 59Open Access
Full Text

Abstract

Background Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR) + NKG2C + adaptive NK cells to maximize missing-self reactivity. Methods We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry and mass cytometry as well as cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). We investigated the functional responses of ADAPT-NK cells against a wide range of tumor target cell lines and primary AML samples using flow cytometry and IncuCyte as well as in a mouse model of AML. Results ADAPT-NK cells were &gt;90% pure with a homogeneous expression of a single self-HLA specific KIR and expanded a median of 470-fold. The ADAPT-NK cells largely retained their adaptive transcriptional signature with activation of effector programs without signs of exhaustion. ADAPT-NK cells showed high degranulation capacity and efficient killing of HLA-C/KIR mismatched tumor cell lines as well as primary leukemic blasts from AML patients. Finally, the expanded adaptive NK cells had preserved robust antibody-dependent cellular cytotoxicity potential and combination of ADAPT-NK cells with an anti-CD16/IL-15/anti-CD33 tri-specific engager led to near-complete killing of resistant CD45 dim blast subtypes. Conclusions These preclinical data demonstrate the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population with full missing-self recognition capability.


Related Papers

No related papers found

Powered by citation graph analysis